Merck announced the first presentation of preliminary data from a phase I clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
In recent months, several directors of cancer centers, appearing on The Directors, a segment of The Cancer Letter Podcast, mentioned that their institutions are increasingly providing small grants—typically in the range of $50,000—to scientists to enable them to keep their labs open.
